%0 Journal Article
%A Liebers, Nora
%A Boumendil, Ariane
%A Finel, Hervé
%A Edelmann, Dominic
%A Kobbe, Guido
%A Baermann, Ben-Niklas
%A Serroukh, Yasmina
%A Blaise, Didier
%A Beelen, Dietrich Wilhelm
%A Solano, Carlos
%A Itälä-Remes, Maija
%A van Meerten, Tom
%A Choi, Goda
%A Schmidt, Susanne A C
%A Kröger, Nicolaus
%A Byrne, Jenny
%A Tudesq, Jean-Jacques
%A Ossami Saidy, Anna
%A Nunes, Ana
%A Siddiqi, Rubina
%A Baro, Elande
%A Zheng, Dan
%A Kloos, Ioana
%A Dreger, Peter
%A Sureda, Anna
%A Glass, Bertram
%A Dietrich, Sascha
%T Brexucabtagene autoleucel versus allogeneic hematopoietic cell transplantation in relapsed and refractory mantle cell lymphoma.
%J Blood cancer discovery
%V 6
%N 3
%@ 2643-3230
%C Philadelphia, PA
%I American Association for Cancer Research
%M DKFZ-2025-00304
%P 182-190
%D 2025
%Z #EA:B340# / 2025 May 5;6(3):182-190
%X Brexucabtagene autoleucel (brexu-cel) and allogeneic hematopoietic cell transplantation (alloHCT) are effective treatments for relapsed or refractory mantle cell lymphoma (r/r MCL), but the optimal choice remains unclear. We conducted an analysis of 64 r/r MCL patients aged ≥50 years treated with brexu-cel in the ZUMA-2 study, matching them 1:1 by propensity score to 64 (out of 272) r/r MCL patients who underwent alloHCT using data from the EBMT registry. Median follow-up time was 36.5 and 34.1 months for the brexu-cel and matched alloHCT cohort, respectively. Brexu-cel patients had a significantly higher overall survival (OS, 81.3
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:39913291
%R 10.1158/2643-3230.BCD-24-0178
%U https://inrepo02.dkfz.de/record/298594